ResMed (RMD) is considered a top growth stock for long-term investors based on analysis tools.

From Nasdaq: 2025-03-17 09:45:10

Zacks Premium offers tools to help investors make informed decisions in the stock market. With features like Zacks Rank, Industry Rank, Equity Research reports, and stock screens, investors can gain confidence and make smarter investment choices. The Zacks Style Scores provide ratings for stocks based on value, growth, and momentum, helping investors identify potential outperformers.

The Zacks Rank is a successful proprietary stock-rating model that leverages earnings estimate revisions to build a strong portfolio. By combining Zacks Rank #1 or #2 stocks with Style Scores of A or B, investors can increase their chances of success. The example of ResMed (RMD), a #3 (Hold) on the Zacks Rank with B VGM Score, showcases how these tools can be used effectively.

ResMed (RMD) is a leading player in the global market for sleep-disordered breathing treatment. With a Growth Style Score of B and positive earnings estimate revisions, RMD shows promise for growth investors. The company’s strong Zacks Rank, top-tier Style Scores, and solid performance make it a stock worth considering for investors looking for growth opportunities.



Read more at Nasdaq: Why ResMed (RMD) is a Top Growth Stock for the Long-Term